Alligator Bioscience (0RK9) Stock Overview
A research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
0RK9 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Alligator Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.20 |
| 52 Week High | SEK 8.40 |
| 52 Week Low | SEK 0.17 |
| Beta | 1.2 |
| 1 Month Change | 3.95% |
| 3 Month Change | -40.82% |
| 1 Year Change | -97.50% |
| 3 Year Change | -99.90% |
| 5 Year Change | n/a |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RK9 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 5.0% | 0.8% | -0.1% |
| 1Y | -97.5% | 24.9% | 18.5% |
Return vs Industry: 0RK9 underperformed the UK Biotechs industry which returned 24.9% over the past year.
Return vs Market: 0RK9 underperformed the UK Market which returned 18.5% over the past year.
Price Volatility
| 0RK9 volatility | |
|---|---|
| 0RK9 Average Weekly Movement | 20.8% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.9% |
Stable Share Price: 0RK9's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RK9's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 11 | Søren Bregenholt | www.alligatorbioscience.se |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG
Alligator Bioscience AB (publ) Fundamentals Summary
| 0RK9 fundamental statistics | |
|---|---|
| Market cap | SEK 101.56m |
| Earnings (TTM) | -SEK 51.35m |
| Revenue (TTM) | SEK 4.42m |
Is 0RK9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RK9 income statement (TTM) | |
|---|---|
| Revenue | SEK 4.42m |
| Cost of Revenue | SEK 77.50m |
| Gross Profit | -SEK 73.07m |
| Other Expenses | -SEK 21.72m |
| Earnings | -SEK 51.35m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 05, 2026
| Earnings per share (EPS) | -0.096 |
| Gross Margin | -1,652.09% |
| Net Profit Margin | -1,160.98% |
| Debt/Equity Ratio | 0% |
How did 0RK9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/16 10:03 |
| End of Day Share Price | 2026/03/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alligator Bioscience AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carl Ramanius | Redeye |
| Filip Lindkvist | Redeye |